Kristian Tage Hansen

Title: The Innovative Work of Kristian Tage Hansen in MIC-1 Compounds

Introduction: Kristian Tage Hansen, an accomplished inventor based in Slangerup, Denmark, has made significant contributions to the field of biomedical research through his innovative developments. With a remarkable portfolio consisting of nine patents, Hansen's work focuses primarily on MIC-1 compounds, which hold potential therapeutic applications.

Latest Patents: Among his latest inventions are two notable patents related to MIC-1 compounds and their uses. The first patent describes compounds comprising a MIC-1 polypeptide paired with an N-terminal amino acid extension. This extension contains 3 to 36 amino acid residues, resulting in a calculated pI lower than 6.5, thus exhibiting MIC-1 activity. The patent emphasizes not only the compounds themselves but also their formulation into pharmaceutical compositions that include acceptable excipients for medical applications. The second patent elaborates on similar MIC-1 compounds, ensuring both the polypeptide and the amino acid extension maintain the same calculated pI condition and pharmacological activity.

Career Highlights: Kristian Tage Hansen is currently employed at Novo Nordisk A/S, a prominent player in the field of healthcare solutions. His role involves extensive research and development activities that leverage his expertise in innovative pharmaceutical applications, particularly concerning the therapeutic uses of MIC-1 compounds.

Collaborations: Throughout his career, Hansen has collaborated with talented coworkers such as Peter Faarup and Louis B Hansen. These collaborations have fostered an environment of creativity and innovation, leading to the development of groundbreaking biomedical solutions that may improve patient outcomes.

Conclusion: Kristian Tage Hansen's contributions to the field of medicine through his inventions of MIC-1 compounds are commendable. With a solid foundation of patents and collaborative efforts, his work continues to pave the way for promising pharmaceutical advancements.